Oxford, UK – 11 March 2014. OGT, The Molecular Genetics Company, has expanded its range of research-validated CytoSure® Molecular Arrays to investigate DNA copy number variation (CNV) underlying a variety of genetic disorders. Designed and optimised in collaboration with experts at Emory Genetics Laboratory (EGL; Atlanta, USA), the arrays are the ideal complement to DNA sequencing, providing a particularly powerful tool for investigating the variety of aberrations underlying genetic disorders. Professor Madhuri Hegde, Professor of Human Genetics at Emory University School of Medicine, will discuss the design and application of these arrays at the American College of Medical Genetics (ACMG) meeting on Thursday 27 March 2014.
Comparative genomic hybridisation arrays (aCGH) are the gold-standard for CNV detection and the 60-mer oligonucleotide probes utilised by OGT’s aCGH platform have been shown to deliver superior CNV detection than alternative platforms. The expanded CytoSure Molecular Array portfolio now enables detection of CNV in genes associated with over 20 genetic disorders, including cardiovascular, inherited eye, intellectual disability and neuromuscular disorders, as well as a range of inherited cancers. In addition, genes covering each disorder can be combined to create bespoke custom arrays, or further customised by the addition of novel content to suit each individual research project.
For the easy extraction of meaningful results from aCGH data, all CytoSure Molecular Arrays are supplied with OGT’s class-leading CytoSure Interpret Software.
Utilising highly targeted, exon-focussed arrays has been shown to detect CNVs as small as 12 bp in size that were missed by targeted NGS.1 Whether used alone or alongside sequencing, CytoSure Molecular Arrays allow researchers to reliably investigate the role of CNV in a wide range of genetic disorders.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read